Laxai Pharma
Laxai Pharma is a Tampa-based, mid-sized contract research organization (CRO) founded in 2004 that provides integrated drug discovery and development services to pharmaceutical sponsors, operating with 51–100 employees under co-founder Vamsi Maddipatla.
- Company typePrivate
- Founded2004
- HeadquartersTampa, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Laxai Pharma does
Laxai Pharma (LAXAI) is a contract research organization (CRO) providing integrated services across the drug discovery and development spectrum. The firm was founded in 2004, is headquartered in Tampa, Florida, and reports a headcount in the 51–100 range, consistent with a mid-sized CRO operating across medicinal chemistry, biology, and development services rather than a large-scale CDMO or Big-Pharma services franchise. Its website is www.laxai.com, and its equity trades on the OTC Pink market under symbol LAXAF, with a delisted status that suggests the company is no longer actively listed on a recognized exchange. The company's co-founder and director, Vamsi Maddipatla, remains in a leadership role, providing continuity from founding.
Business-model and customer detail in the source material is sparse: no customer logos, segment mix, pricing schedule, or revenue figure is disclosed. The available commercial signal is a Q1 2026 SOCMA membership, indicating the firm remains engaged with the U.S. specialty and contract chemicals trade association and is operationally active. The only documented inorganic move is the 2010-03-11 acquisition of OSR Solutions, for an undisclosed consideration, which broadened LAXAI's service portfolio early in its operating history. No subsequent M&A, fundraising, product launch, partnership, or geographic expansion is recorded in the input data, leaving the present commercial footprint — clients served, therapeutic areas covered, geographic reach, and revenue scale — substantially undocumented for analytical purposes.
Laxai Pharma firmographics
Firmographics- Name
- Laxai Pharma
- Website
- https://laxai.com
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Laxai Pharma is a Tampa-based, mid-sized contract research organization (CRO) founded in 2004 that provides integrated drug discovery and development services to pharmaceutical sponsors, operating with 51–100 employees under co-founder Vamsi Maddipatla.
- Ownership category
- akta.pro rank
Laxai Pharma industry classification
Industry- Product category
- Contract Research Organization (CRO) Services
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)
- akta.pro secondary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
Keywords
Where Laxai Pharma is headquartered
LocationHeadquarters
- HQ city
- Tampa
- HQ country
- United States
- HQ region
- North America
Markets served
Laxai Pharma business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D
Laxai Pharma product offering
Product offeringCore offering
Laxai Pharma is a Contract Research Organization (CRO) that provides integrated research services across the drug discovery and development spectrum. Its service portfolio spans medicinal chemistry, biology, DMPK, and clinical development, serving pharmaceutical and biotech sponsors that need external scientific capacity to advance therapeutic programs.
Differentiator
Problem solved
Functional benefit
Products and services
- Integrated Drug Discovery and Development Services Integrated Contract Research Organization services spanning medicinal chemistry, biology, DMPK, and clinical development, delivered to pharmaceutical and biotech sponsors that need end-to-end research support across the drug discovery and development spectrum.
Companies that use Laxai Pharma
Customer profileIdeal customer profiles1 record
Laxai Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Laxai Pharma partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights2 records
Laxai Pharma competitors and assessment
Company assessmentDirect peers
- Jubilant Biosys: India-based integrated discovery CRO offering medicinal chemistry, in vitro/in vivo biology, and DMPK. Closely matches Laxai's discovery CRO positioning and competes for the same US/EU sponsor outsourcing programs.
- Medpace: Mid-sized CRO focused on full-service clinical development for small-to-mid biopharma. Comparable to Laxai in the mid-tier CRO positioning and similarly competes for outsourced pharma R&D budgets, though Medpace is clinical-stage focused.
- WuXi AppTec: Global CRO/CDMO with a major drug discovery and preclinical services platform. Directly competes with Laxai in medicinal chemistry, DMPK, and biology services for pharma sponsors, and is a primary benchmark for outsourced discovery pricing.
- Eurofins Discovery: Discovery and preclinical services arm of Eurofins Scientific, offering medicinal chemistry, in vitro pharmacology, and DMPK. Directly comparable to Laxai's chemistry-led discovery service portfolio and serves similar small-to-mid biopharma clients.
- Syngene International: India-based integrated CRO/CDMO with strong discovery, medicinal chemistry, and biology capabilities. Highly comparable service model to Laxai's discovery-focused positioning, often competing for the same US/EU sponsor programs.
- Pharmaron: China/UK/US-headquartered CRO offering integrated drug discovery, DMPK, and preclinical services. Closely comparable to Laxai's integrated discovery offering, with similar service scope but significantly larger scale and global footprint.
Broad incumbents
- IQVIA: World's largest CRO with full clinical and laboratory services across the development spectrum. Overlaps with Laxai at the broader CRO-services level and is the dominant preferred-vendor competitor for sponsor R&D budgets.
- Charles River Laboratories: Large global CRO with extensive discovery, preclinical, and safety assessment services. Directly comparable to Laxai's preclinical/discovery positioning but at vastly greater scale, serving the same pharma/biotech sponsor base.
- Labcorp Drug Development (Fortrea): Major clinical and preclinical CRO spun out from Labcorp, offering discovery through Phase IV services. Comparable to Laxai as a full-spectrum development CRO but at vastly larger scale, with broader sponsor relationships.
Emerging players
- BioDuro: Mid-sized CRO/CDMO offering drug discovery, DMPK, and formulation services with US-China operations. Comparable to Laxai in the integrated discovery niche, often competing on cost for small-molecule programs.
Market position
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Laxai Pharma social profiles
Digital presenceLaxai Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Laxai Pharma leadership team
Management profileNumber of profiles
Profiles1 record
Laxai Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Laxai Pharma M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Laxai Pharma
What does Laxai Pharma do?
Laxai Pharma is a Contract Research Organization (CRO) that provides integrated research services across the drug discovery and development spectrum. Its service portfolio spans medicinal chemistry, biology, DMPK, and clinical development, serving pharmaceutical and biotech sponsors that need external scientific capacity to advance therapeutic programs.
Is Laxai Pharma a public or private company?
Laxai Pharma is a private company. It is classified as unknown and is currently operating.
When was Laxai Pharma founded?
Laxai Pharma was founded in 2004. It employs 51 to 100 people.
Where is Laxai Pharma based?
Laxai Pharma is headquartered in Tampa, United States, in the North America region.
Who are Laxai Pharma's main competitors?
Direct peers on record are Jubilant Biosys, Medpace, WuXi AppTec, Eurofins Discovery, Syngene International and Pharmaron. Broad incumbents are IQVIA, Charles River Laboratories and Labcorp Drug Development (Fortrea). BioDuro is listed as an emerging player.
Does Laxai Pharma have an API?
No public API is recorded for Laxai Pharma.
What industry is Laxai Pharma in?
Laxai Pharma's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 5417 and its SIC code is 2833.